Search

Your search keyword '"Barrios, Carlos A."' showing total 1,699 results
Start Over Author "Barrios, Carlos A."
1,699 results on '"Barrios, Carlos A."'

51. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial.

Author

Yardley, Denise A., primary, Untch, Michael, additional, Barrios, Carlos H., additional, Bardia, Aditya, additional, Kalinsky, Kevin, additional, Im, Seock-Ah, additional, Chia, Stephen K. L., additional, Ring, Alistair E., additional, McAndrew, Nicholas Patrick, additional, Valero, Vicente, additional, Ruiz-Borrego, Manuel, additional, Fresco, Rodrigo, additional, Sum, Eleanor, additional, Chattar, Yogesh, additional, Waters, Sorcha, additional, and Harbeck, Nadia, additional

Published
2024
Full Text
View/download PDF

52. Non-basal subtype defined by FOXC1 expression as an independent predictor of capecitabine efficacy in the triple negative breast cancer GEICAM/2003-11_CIBOMA/2004-01 trial.

Author

Rojo Todo, Federico Gustavo, primary, Taylor, Clive R., additional, Barrios, Carlos H., additional, Torrecillas, Laura, additional, Ruiz-Borrego, Manuel, additional, Bines, Jose, additional, Segalla, Jose G.M, additional, Guerrero, Angel, additional, García-Sáenz, Jose A., additional, Torres, Roberto, additional, De La Haba, Juan, additional, Ayala, Francisco, additional, Gomez, Henry Leonidas, additional, Llombart, Antonio, additional, Herranz, Jesús, additional, Rincon, Raul, additional, Caballero, Rosalia, additional, Bermejo, Begona, additional, Ray, Partha S, additional, and Martin, Miguel, additional

Published
2024
Full Text
View/download PDF

56. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1–Selected NSCLC

Author

Jassem, Jacek, de Marinis, Filippo, Giaccone, Giuseppe, Vergnenegre, Alain, Barrios, Carlos H., Morise, Masahiro, Felip, Enriqueta, Oprean, Cristina, Kim, Young-Chul, Andric, Zoran, Mocci, Simonetta, Enquist, Ida, Komatsubara, Kimberly, McCleland, Mark, Kuriki, Hiroshi, Villalobos, Monette, Phan, See, Spigel, David R., and Herbst, Roy S.

Published
2021
Full Text
View/download PDF

57. Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean

Author

Werutsky, Gustavo, Barrios, Carlos H, Cardona, Andres F, Albergaria, André, Valencia, Alfonso, Ferreira, Carlos G, Rolfo, Christian, de Azambuja, Evandro, Rabinovich, Gabriel A, Sposetti, Georgina, Arrieta, Oscar, Dienstmann, Rodrigo, Rebelatto, Taiane F, Denninghoff, Valeria, Aran, Veronica, and Cazap, Eduardo

Published
2021
Full Text
View/download PDF

58. Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward

Author

Barrios, Carlos H, Werutsky, Gustavo, Mohar, Alejandro, Ferrigno, Ana S, Müller, Bettina G, Bychkovsky, Brittany L, Castro E, Carlos José, Uribe, Claudia J, Villarreal-Garza, Cynthia, Soto-Perez-de-Celis, Enrique, Gutiérrez-Delgado, Francisco, Kim, Ji Seok, Ismael, Julia, Delgado, Lucia, Santini, Luiz A, Teich, Nelson, Chavez, Pamela C, Liedke, Pedro E R, Exman, Pedro, Barroso-Sousa, Romualdo, Stefani, Stephen D, Cáceres, Suyapa A Bejarano, Rebelatto, Taiane F, Pastrana, Tania, Chavarri-Guerra, Yanin, Vargas, Yolanda, and Cazap, Eduardo

Published
2021
Full Text
View/download PDF

59. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

Author

Aebi, Stephan, André, Fabrice, Barrios, Carlos, Bergh, Jonas, Bonnefoi, Herve, Bretel Morales, Denisse, Brucker, Sara, Burstein, Harold, Cameron, David, Cardoso, Fatima, Carey, Lisa, Chua, Boon, Ciruelos, Eva, Colleoni, Marco, Curigliano, Giuseppe, Delaloge, Suzette, Denkert, Carsten, Dubsky, Peter, Ejlertsen, Bent, Fitzal, Florian, Francis, Prudence, Galimberti, Viviana, Gamal El Din Mohamed Mahmoud, Hebatallah, Garber, Judy, Gnant, Michael, Gradishar, William, Gulluoglu, Bahadir, Harbeck, Nadia, Huang, Chiun-Sheng, Huober, Jens, Ilbawi, Andre, Jiang, Zefei, Johnston, Steven, Lee, Eun Sook, Loibl, Sibylle, Morrow, Monica, Partridge, Ann, Piccart, Martine, Poortmans, Philip, Prat, Aleix, Regan, Meredith, Rubio, Isabella, Rugo, Hope, Rutgers, Emiel, Sedlmayer, Felix, Semiglazov, Vladimir, Senn, Hans-Joerg, Shao, Zhiming, Spanic, Tanja, Tesarova, Petra, Thürlimann, Beat, Tjulandin, Sergei, Toi, Masakazu, Trudeau, Maureen, Turner, Nicholas, Vaz Luis, Inez, Viale, Giuseppe, Watanabe, Toru, Weber, Walter P., Winer, Eric P., Xu, Binghe, Burstein, H.J., Curigliano, G., Thürlimann, B., Weber, W.P., Poortmans, P., Regan, M.M., Senn, H.J., Winer, E.P., and Gnant, M.

Published
2021
Full Text
View/download PDF

61. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Author

Hilbers, Florentine, El-Abed, Sarra, Balta, Vasiliki, Schurmans, Celine, Rosa, Daniela D., Saini, Kamal, Filho, Otto Metzger, McConnell, Robin, Paterson, Vicki, Campbell, Christine, McFadden, Eleanor, Paterson, Emma, Kassab, Garrick, Moreno-Aspitia, Alvaro, Holmes, Eileen M., Jackisch, Christian, de Azambuja, Evandro, Boyle, Frances, Hillman, David W., Korde, Larissa, Fumagalli, Debora, Izquierdo, Miguel A., McCullough, Ann E., Wolff, Antonio C., Pritchard, Kathleen I., Untch, Michael, Guillaume, Sébastien, Ewer, Michael S., Shao, Zhimin, Sim, Sung Hoon, Aziz, Zeba, Demetriou, Georgia, Mehta, Ajay O., Andersson, Michael, Toi, Masakazu, Lang, Istvan, Xu, Binghe, Smith, Ian E., Barrios, Carlos H., Baselga, Jose, Gelber, Richard D., and Piccart-Gebhart, Martine

Published
2021
Full Text
View/download PDF

62. On-Chip Biosensing and Gas Sensing by Photonic Slot Waveguides: A Review

Author

Dell'Olio, Francesco and Angulo Barrios, Carlos

Abstract

Photonic slot waveguides enhance light-matter interactions by confining the optical field in regions with a low refractive index, making them highly effective for detecting a wide range of biological and chemical analytes. This article reviews the application of photonic slot waveguides in biosensing and gas sensing, showcasing their ability to be integrated into on-chip platforms often intended for point-of-care testing with enhanced sensitivity and specificity. In biosensing, these waveguides are particularly suited for applications in medical diagnostics and environmental monitoring, allowing for the detection of biomarkers and other biological molecules with high sensitivity. For gas sensing, photonic slot waveguides have been employed effectively in the near-infrared and mid-infrared spectrum to detect various gases, including hazardous and greenhouse gases, which is crucial for both industrial safety and environmental protection. This review also explores the potential of these waveguides in noninvasive diagnostic methods, such as liquid biopsy, breath analysis, and breath biopsy, which offer new avenues for early disease detection and monitoring. By summarizing recent advancements and outlining future directions, this review underscores the transformative potential of photonic slot waveguides in advancing on-chip sensing technologies across multiple fields.

Published
2025
Full Text
View/download PDF

63. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Author

Chan, Arlene, Moy, Beverly, Mansi, Janine, Ejlertsen, Bent, Holmes, Frankie Ann, Chia, Stephen, Iwata, Hiroji, Gnant, Michael, Loibl, Sibylle, Barrios, Carlos H., Somali, Isil, Smichkoska, Snezhana, Martinez, Noelia, Alonso, Mirta Garcia, Link, John S., Mayer, Ingrid A., Cold, Søren, Murillo, Serafin Morales, Senecal, Francis, Inoue, Kenichi, Ruiz-Borrego, Manuel, Hui, Rina, Denduluri, Neelima, Patt, Debra, Rugo, Hope S., Johnston, Stephen R.D., Bryce, Richard, Zhang, Bo, Xu, Feng, Wong, Alvin, and Martin, Miguel

Published
2021
Full Text
View/download PDF

66. Surgical Precision of MICA and Reverdin-Isham Using 3D-Printed Guides: A Cadaveric Study.

Author

Fernández-Ehrling, Nadia, Nieto-García, Eduardo, Ramirez-Andrés, Leonor, Nieto-González, Elena, Barrios, Carlos, García-Vicente, Sergio, and Ferrer-Torregrosa, Javier

Subjects
LEARNING curve, MINIMALLY invasive procedures, HALLUX valgus, SURGICAL complications, THREE-dimensional printing
Abstract

Background/Objectives: Hallux valgus is a common foot deformity that requires surgical correction to restore proper alignment. Precision in the osteotomies performed during these surgeries is critical to avoid complications and improve outcomes. However, variability in surgeon experience can negatively affect precision. In this context, advances in 3D printing have enabled the development of customized surgical guides, which may enhance precision and reduce variability among surgeons with different levels of expertise. This study aims to evaluate the effectiveness of a 3D-printed surgical guide in minimally invasive hallux valgus correction, focusing on the accuracy of osteotomies performed by novice surgeons, experienced surgeons, and theoretically trained consultants. Methods: An ex vivo study was performed with 30 cadaveric feet, divided into three groups according to the level of experience of the surgeons: 3D guide group, Master's students, professionals. All surgeons performed Akin and Reverdin-Isham osteotomies, but the experimental group (the 3D guide group) utilized a customized 3D-printed surgical guide for enhanced precision during these procedures. Radiographic measurements of osteotomy angles and alignment were taken after the interventions, and compared with the planned values. Statistical analyses were conducted to evaluate the variability in the precision of the cuts. Results: The use of the 3D-printed surgical guide significantly reduced angular variability in the experienced group, achieving higher levels of accuracy than experienced surgeons. Effect sizes, which ranged from small to large, indicated a greater impact on angle measurements (η2 = 0.46, p < 0.001); no significant differences were found between the groups in other evaluated parameters. Conclusions: The incorporation of 3D-printed surgical guides in hallux valgus surgery significantly improves osteotomy accuracy, particularly in less experienced surgeons. This suggests that these guides can help standardize procedures, reduce the learning curve, and lower intraoperative complications. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

67. Comparison of the Minimally Invasive Reverdin–Isham Lateral Translation Osteotomy Versus the Standard Reverdin–Isham Technique: A Pilot Prospective Cohort Study.

Author

Belda-Donat, Maria, Marti-Martinez, Luis M., Lorca-Gutierrez, Rubén, Naranjo-Ruiz, Carmen, Chacón-Giráldez, Fernando, and Barrios, Carlos

Subjects
HALLUX valgus, MINIMALLY invasive procedures, ANATOMICAL planes, OPERATIVE surgery, PAIN management
Abstract

Background/Objectives: Reverdin–Isham osteotomy is effective in correcting moderate hallux valgus deformity but has certain limitations when correcting a deformity in the sagittal plane. This study aimed to evaluate the impact on pain, functionality, and radiological measures of angular corrections, and the safety of the Reverdin–Isham lateral translation technique through minimally invasive surgery in the treatment of a moderate hallux valgus compared to Reverdin–Isham standard osteotomy. Methods: A pilot 6-month prospective cohort study was conducted on adults over 18 years old with a hallux valgus in at least one foot. The study exposure was the use of the Reverdin–Isham lateral translation technique. The outcome variables were pain and functionality through VAS and AOFAS scales, respectively, and radiological measurements of the first toe metatarsophalangeal angle (MPA), first space intermetatarsal angle (IMA), proximal articular set angle (PASA), distal articular set angle (DASA), metatarsal formula, and position of sesamoids in the AP projection. Results: The study involved 60 participants. Results indicate significant reductions in pain and radiological measures in both cohorts: MPA improved by 23.13 degrees, IMA by 5.93 degrees, and sesamoid position by 4.23 degrees in patients who underwent the lateral translation technique versus 13.20, 3.30, and 1.57 degrees, respectively, in patients who experienced the standard Reverdin–Isham technique. The lateral translation method showed greater reductions in these metrics compared to the standard Reverdin–Isham technique (p < 0.05). Conclusions: Percutaneous Reverdin–Isham techniques, both standard and with lateral translations, effectively corrected moderate hallux valguses. However, the lateral translation method provided greater reductions in MPA, IMA, and sesamoid positions, making it more suitable for deformities with IMAs over 15 degrees. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

69. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Author

Luis, Fein, Gonzalo, Gomez Abuin, Diego, Kaen, Ruben, Kowalwszyn, Matias, Molina, Mirta, Varela, Sally, Baron-Hay, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Andrea, Gombos, Donatienne, Taylor, Carlos, Barrios, Leandro, Brust, Fabiano, Costa, Ruffo, de Freitas Junior, Roberto, Hegg, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Roberto Odebrecht, Rocha, Antonio Orlando, Scalabrini Neto, Felipe, Silva, David, Cescon, Danielle, Charpentier, Cristiano, Ferrario, Xinni, Song, Joanne, Yu, Alejandro, Acevedo, Carlos, Gallardo, Claudio, Salas, Cesar, Sanchez, Eduardo, Yanez, Alvaro, Gomez Diaz, Jesus, Sanchez, Petra, Holeckova, Zdenek, Kral, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Vesna, Glavicic, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Anthony, Goncalves, Anne-Claire, Hardy-Bessard, Luis, Teixeira, Jens-Uwe, Blohmer, Peter, Fasching, Dirk, Forstmeyer, Nadia, Harbeck, Jens, Huober, Anna, Kaczerowsky Flores de Sousa, Christian, Kurbacher, Sibylle, Loibl, Diana, Lueftner, Tjoung-Won, Park-Simon, Raquel Von, Schumann, Pauline, Wimberger, Louis, Chow, Ava, Kwong, Kai Cheong Roger, Ngan, Peter, Arkosy, Tibor, Csoszi, Zsuzsanna, Kahan, Laszlo, Landherr, Karoly, Mahr, Gabor, Rubovszky, John, Crown, Catherine, Kelly, Seamus, O'Reilly, Saverio, Cinieri, Antonietta, DAlessio, Enrico, Ricevuto, Tomoyuki, Aruga, Takaaki, Fujii, Kenichi, Inoue, Takashi, Ishikawa, Yoshinori, Ito, Tsutomu, Iwasa, Hiroji, Iwata, Yoshimasa, Kosaka, Koji, Matsumoto, Yasuo, Miyoshi, Hirofumi, Mukai, Seigo, Nakamura, Naoki, Niikura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Eiji, Suzuki, Masato, Takahashi, Yuko, Tanabe, Kenji, Tamura, Koichiro, Tsugawa, Junichiro, Watanabe, Naohito, Yamamoto, Yutaka, Yamamoto, Teruo, Yamauchi, Anita, Bustam, Mastura, Md Yusof, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Jorge, Martinez Rodriguez, Flavia, Morales-Vasquez, Jessica, Reyes Contreras, Karin, Beelen, Vivianne, Tjan-Heijnen, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Cezary, Szczylik, Rafal, Tarnawski, Bogdan, Zurawski, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Andrey, Meshcheryakov, Vladimir, Moiseyenko, Guzel, Mukhametshina, Jin Hee, Ahn, Seock-Ah, Im, Keun Seok, Lee, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Josefina, Cruz Jurado, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Esther, Holgado, Esther, Zamora Adelantado, Chien-Ting, Liu, Mei-Ching, Liu, Chiun-Sheng, Huang, Chao-Jung, Tsao, Ling-Ming, Tseng, Cagatay, Arslan, Gul, Basaran, Irfan, Cicin, Erhan, Gokmen, Seyda, Gunduz, Nil, Molinas Mandel, Mustafa, Ozguroglu, Ozgur, Ozyilkan, Sinan, Yavuz, Steve, Chan, Janine, Graham, Iain, MacPherson, Peter, Schmid, Nicholas, Turner, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Hryhoriy, Adamchuk, Oleksandr, Berzoy, Igor, Bondarenko, Oleksii, Kolesnik, Olena, Kolesnik, Hanna, Komisarenko, Anna, Kryzhanivska, Iurii, Leshchenko, Alla, Nasonova, Natalya, Otchenash, Olga, Ponomarova, Andrii, Rusyn, Sergii, Shevnya, Yaroslav, Shparyk, Dmytro, Trukhin, Grygorii, Ursol, Ihor, Vynnychenko, Sibel, Blau, Madhu, Chaudhry, Michael, Chung, Patrick, Cobb, Scott, Cole, Jennifer, Diamond, Keerthi, Gogineni, Jeffrey, Hargis, Kent, Hoskins, William, Irvin, Randa, Loutfi, Janice, Lu, Raul, Mena, Susan, Moore, Rita, Nanda, Ira, Oliff, Coral, Omene, Timothy, Panella, Amit, Panwalkar, Brian, Patson, Hope, Rugo, Irina, Rybalova, Michael, Schleider, Robert, Siegel, Michael, Simon, Laura, Stampleman, Bradley, Sumrall, Michaela, Tsai, Frances, Valdes-Albini, Cortes, Javier, Cescon, David W, Rugo, Hope S, Nowecki, Zbigniew, Im, Seock-Ah, Yusof, Mastura Md, Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Gokmen, Erhan, Loi, Sherene, Guo, Zifang, Zhao, Jing, Aktan, Gursel, Karantza, Vassiliki, and Schmid, Peter

Published
2020
Full Text
View/download PDF

70. Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non–Small-Cell Lung Cancer

Author

Gelatti, Ana C.Z., Cordeiro de Lima, Vladmir C., Freitas, Helano, Werutsky, Gustavo, Gaiger, Ana Maria, Klock, Clovis, Viola, Patricia P., Shiang, Christina, de Macedo, Mariana P., Lopes, Lisandro F., De Marchi, Pedro, Albino da Silva, Eduardo Caetano, Moura, Fernando, Borges, Giuliano, Zaffaroni, Facundo, Nunes Filho, Paulo Ricardo, Araujo, Luiz H., Mascarenhas, Eldsamira, Mathias, Clarissa, Barrios, Carlos, and Zukin, Mauro

Published
2020
Full Text
View/download PDF

71. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

Author

Mittendorf, Elizabeth A, Zhang, Hong, Barrios, Carlos H, Saji, Shigehira, Jung, Kyung Hae, Hegg, Roberto, Koehler, Andreas, Sohn, Joohyuk, Iwata, Hiroji, Telli, Melinda L, Ferrario, Cristiano, Punie, Kevin, Penault-Llorca, Frédérique, Patel, Shilpen, Duc, Anh Nguyen, Liste-Hermoso, Mario, Maiya, Vidya, Molinero, Luciana, Chui, Stephen Y, and Harbeck, Nadia

Published
2020
Full Text
View/download PDF

73. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC

Author

Gascón, Pere, Nagarkar, Rajnish, Šmakal, Martin, Syrigos, Konstantinos N., Barrios, Carlos H., Sánchez, Jesús Cárdenas, Zhang, Li, Henry, David H., Gordon, David, Hirsh, Vera, Kubota, Kaoru, Orlov, Sergey, Thomas, Gary, Steinmetz, Tilman, Kang, Jin-Hyoung, Tomita, Dianne K., Fleishman, Alexander N., Park, Joseph K., and De Oliveira Brandao, Cisio

Published
2020
Full Text
View/download PDF

75. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Author

Rittmeyer, Achim, Barlesi, Fabrice, Waterkamp, Daniel, Park, Keunchil, Ciardiello, Fortunato, von Pawel, Joachim, Gadgeel, Shirish M, Hida, Toyoaki, Kowalski, Dariusz M, Dols, Manuel Cobo, Cortinovis, Diego L, Leach, Joseph, Polikoff, Jonathan, Barrios, Carlos, Kabbinavar, Fairooz, Frontera, Osvaldo Arén, De Marinis, Filippo, Turna, Hande, Lee, Jong-Seok, Ballinger, Marcus, Kowanetz, Marcin, He, Pei, Chen, Daniel S, Sandler, Alan, Gandara, David R, and Group, OAK Study

Subjects
Clinical Research, Cancer, Clinical Trials and Supportive Activities, Lung, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Docetaxel, Drug Administration Schedule, Female, Humans, Infusions, Intravenous, Kaplan-Meier Estimate, Lung Neoplasms, Male, Middle Aged, Taxoids, Treatment Outcome, OAK Study Group, Medical and Health Sciences, General & Internal Medicine
Abstract

BackgroundAtezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interactions, reinvigorating anticancer immunity. We assessed its efficacy and safety versus docetaxel in previously treated patients with non-small-cell lung cancer.MethodsWe did a randomised, open-label, phase 3 trial (OAK) in 194 academic or community oncology centres in 31 countries. We enrolled patients who had squamous or non-squamous non-small-cell lung cancer, were 18 years or older, had measurable disease per Response Evaluation Criteria in Solid Tumors, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had received one to two previous cytotoxic chemotherapy regimens (one or more platinum based combination therapies) for stage IIIB or IV non-small-cell lung cancer. Patients with a history of autoimmune disease and those who had received previous treatments with docetaxel, CD137 agonists, anti-CTLA4, or therapies targeting the PD-L1 and PD-1 pathway were excluded. Patients were randomly assigned (1:1) to intravenously receive either atezolizumab 1200 mg or docetaxel 75 mg/m2 every 3 weeks by permuted block randomisation (block size of eight) via an interactive voice or web response system. Coprimary endpoints were overall survival in the intention-to-treat (ITT) and PD-L1-expression population TC1/2/3 or IC1/2/3 (≥1% PD-L1 on tumour cells or tumour-infiltrating immune cells). The primary efficacy analysis was done in the first 850 of 1225 enrolled patients. This study is registered with ClinicalTrials.gov, number NCT02008227.FindingsBetween March 11, 2014, and April 29, 2015, 1225 patients were recruited. In the primary population, 425 patients were randomly assigned to receive atezolizumab and 425 patients were assigned to receive docetaxel. Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations. In the ITT population, overall survival was improved with atezolizumab compared with docetaxel (median overall survival was 13·8 months [95% CI 11·8-15·7] vs 9·6 months [8·6-11·2]; hazard ratio [HR] 0·73 [95% CI 0·62-0·87], p=0·0003). Overall survival in the TC1/2/3 or IC1/2/3 population was improved with atezolizumab (n=241) compared with docetaxel (n=222; median overall survival was 15·7 months [95% CI 12·6-18·0] with atezolizumab vs 10·3 months [8·8-12·0] with docetaxel; HR 0·74 [95% CI 0·58-0·93]; p=0·0102). Patients in the PD-L1 low or undetectable subgroup (TC0 and IC0) also had improved survival with atezolizumab (median overall survival 12·6 months vs 8·9 months; HR 0·75 [95% CI 0·59-0·96]). Overall survival improvement was similar in patients with squamous (HR 0·73 [95% CI 0·54-0·98]; n=112 in the atezolizumab group and n=110 in the docetaxel group) or non-squamous (0·73 [0·60-0·89]; n=313 and n=315) histology. Fewer patients had treatment-related grade 3 or 4 adverse events with atezolizumab (90 [15%] of 609 patients) versus docetaxel (247 [43%] of 578 patients). One treatment-related death from a respiratory tract infection was reported in the docetaxel group.InterpretationTo our knowledge, OAK is the first randomised phase 3 study to report results of a PD-L1-targeted therapy, with atezolizumab treatment resulting in a clinically relevant improvement of overall survival versus docetaxel in previously treated non-small-cell lung cancer, regardless of PD-L1 expression or histology, with a favourable safety profile.FundingF. Hoffmann-La Roche Ltd, Genentech, Inc.

Published
2017

79. The Lancet Breast Cancer Commission

Author

Coles, Charlotte E, primary, Earl, Helena, additional, Anderson, Benjamin O, additional, Barrios, Carlos H, additional, Bienz, Maya, additional, Bliss, Judith M, additional, Cameron, David A, additional, Cardoso, Fatima, additional, Cui, Wanda, additional, Francis, Prudence A, additional, Jagsi, Reshma, additional, Knaul, Felicia Marie, additional, McIntosh, Stuart A, additional, Phillips, Kelly-Anne, additional, Radbruch, Lukas, additional, Thompson, Mareike K, additional, André, Fabrice, additional, Abraham, Jean E, additional, Bhattacharya, Indrani S, additional, Franzoi, Maria Alice, additional, Drewett, Lynsey, additional, Fulton, Alexander, additional, Kazmi, Farasat, additional, Inbah Rajah, Dharrnesha, additional, Mutebi, Miriam, additional, Ng, Dianna, additional, Ng, Szeyi, additional, Olopade, Olufunmilayo I, additional, Rosa, William E, additional, Rubasingham, Jeffrey, additional, Spence, Dingle, additional, Stobart, Hilary, additional, Vargas Enciso, Valentina, additional, Vaz-Luis, Ines, additional, Villarreal-Garza, Cynthia, additional, Arreola-Ornelas, Hector, additional, Bhadelia, Afsan, additional, Boughey, Judy C, additional, Chatterjee, Sanjoy, additional, Dodwell, David, additional, Doubova, Svetlana, additional, Du Plooy, Dorothy, additional, Essue, Beverley, additional, Goel, Neha, additional, Gralow, Julie, additional, Hawley, Sarah, additional, Kiely, Belinda, additional, Mann, Ritse, additional, Mertz, Shirley, additional, Palmieri, Carlo, additional, Poortmans, Philip, additional, Spanic, Tanja, additional, Stephen, Lesley, additional, Symmans, Fraser, additional, Towns, Catherine, additional, Verhoeven, Didier, additional, Vinnicombe, Sarah, additional, Watkins, David, additional, Yip, Cheng-Har, additional, and Zikmund-Fisher, Brian, additional

Published
2024
Full Text
View/download PDF

84. Data from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

85. Supplementary Tables and Figures 1 from First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results

Author

Schmid, Peter, primary, Turner, Nicholas C., primary, Barrios, Carlos H., primary, Isakoff, Steven J., primary, Kim, Sung-Bae, primary, Sablin, Marie-Paule, primary, Saji, Shigehira, primary, Savas, Peter, primary, Vidal, Gregory A., primary, Oliveira, Mafalda, primary, O'Shaughnessy, Joyce, primary, Italiano, Antoine, primary, Espinosa, Enrique, primary, Boni, Valentina, primary, White, Shane, primary, Rojas, Beatriz, primary, Freitas-Junior, Ruffo, primary, Chae, Yeesoo, primary, Bondarenko, Igor, primary, Lee, Jieun, primary, Torres Mattos, Cesar, primary, Martinez Rodriguez, Jorge Luis, primary, Lam, Lisa H., primary, Jones, Surai, primary, Reilly, Sarah-Jayne, primary, Huang, Xiayu, primary, Shah, Kalpit, primary, and Dent, Rebecca, primary

Published
2024
Full Text
View/download PDF

89. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Schmid, Peter, Rugo, Hope S, Adams, Sylvia, Schneeweiss, Andreas, Barrios, Carlos H, Iwata, Hiroji, Diéras, Véronique, Henschel, Volkmar, Molinero, Luciana, Chui, Stephen Y, Maiya, Vidya, Husain, Amreen, Winer, Eric P, Loi, Sherene, and Emens, Leisha A

Published
2020
Full Text
View/download PDF

91. Autoeficacia para brindar cuidados humanizados por parte del personal de enfermería

Author

Mansilla, Alejandra, Canova Barrios, Carlos, Mansilla, Alejandra, and Canova Barrios, Carlos

Abstract

Objective: To evaluate the perception of self-efficacy to provide humanized care by the nursing staff of a health institution specialized in rehabilitation in the city of Buenos Aires, Argentina, during the first semester of 2023. Methodology: Descriptive, cross-sectional, and quantitative study. Coates' Caring Efficacy Scale instrument was implemented in its Spanish version with a Cronbach's alpha of 0.91. Informed consent was obtained, and no data were collected. Results: Respondents had a mean age of 38.29 years (SD: 8.00) and were mostly women, single, with children, trained as nurses, with a technical degree in nursing, performing care activities, and with more than 5 years of work experience. The item with the best rating was "If I think a client/patient is uncomfortable or might need help, I approach that person" with a mean of 5.07 (SD:1.52) categorized as "moderately agree", while the item with the worst rating was "I often find it difficult to make my point to patients/clients when I need to" with a mean of 2.44 (SD:1.56) categorized as "moderately disagree". The mean self-efficacy to provide humanized care was 148.13 (SD:23.75), categorized as moderately positive. Conclusions: The perception of self-efficacy to provide humanized care was positive and negatively related to the performance of care activities. There is a need to implement strategies to prevent dehumanization among caregivers and to implement training activities to improve care., Objetivo: Evaluar la percepción de autoeficacia para brindar cuidados humanizados por parte del personal de enfermería de una institución sanitaria especializada en rehabilitación de la Ciudad de Buenos Aires, Argentina durante el primer semestre del 2023. Metodología: Estudio descriptivo, transversal y cuantitativo. Se implementó el instrumento Caring Efficacy Scale de Coates en su versión en español con un alfa de Cronbach de 0,91. Se implementó el consentimiento informado y no se recolectaron datos filiatorios. Resultados: Los encuestados tuvieron una media de edad de 38,29 años (DE:8,00), y eran mayormente mujeres, solteras, con hijos, con formación de tecnicatura en Enfermería, desempeñaban actividades asistenciales y tenían más de 5 años de experiencia laboral. El ítem con mejor valoración fue “Si pienso que un cliente/paciente está incómodo o puede necesitar ayuda, me acerco a esa persona” con una media de 5,07 (DE:1,52) categorizado como “Moderadamente de acuerdo”, mientras, el ítem con peor valoración fue “A menudo encuentro difícil transmitir mi punto de vista a los pacientes/clientes cuando lo necesito” con una media de 2,44 (DE:1,56) categorizado como “Moderadamente en desacuerdo”. La media de autoeficacia para brindar cuidados humanizados fue de 148,13 (DE:23,75) categorizado como moderadamente positivo. Conclusión: La percepción de autoeficacia para brindar cuidados humanizados fue positiva y se relacionó negativamente con la realización de actividades asistenciales. Se amerita de implementar estrategias para prevenir la deshumanización en el personal de enfermería, así como implementar actividades de capacitación para mejorar la atención.

Published
2024

93. The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)

Author

Rosa, Daniela Dornelles, Bines, José, Werutsky, Gustavo, Barrios, Carlos Henrique, Cronemberger, Eduardo, Queiroz, Geraldo Silva, de Lima, Vladmir C. Cordeiro, Freitas-Júnior, Ruffo, Couto, José d’Oliveira, Emerenciano, Karla, Resende, Heloísa, Crocamo, Susane, Reinert, Tomás, Van Eyil, Brigitte, Nerón, Yeni, Dybal, Vanessa, Lazaretti, Nicolas, de Cassia Costamilan, Rita, de Andrade, Diocésio Alves Pinto, Mathias, Clarissa, Vacaro, Giovana Zerwes, Borges, Giuliano, Morelle, Alessandra, Caleffi, Maira, Filho, Carlos Sampaio, Mano, Max S., Zaffaroni, Facundo, de Jesus, Rafaela Gomes, and Simon, Sergio Daniel

Published
2020
Full Text
View/download PDF

95. Methodology for Tailored Linux Distributions Development for HPC Embedded Systems

Author

Díaz, Gilberto, Rojas, Pablo, Barrios, Carlos, Barbosa, Simone Diniz Junqueira, Editorial Board Member, Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Kotenko, Igor, Editorial Board Member, Yuan, Junsong, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Washio, Takashi, Founding Editor, Meneses, Esteban, editor, Castro, Harold, editor, Barrios Hernández, Carlos Jaime, editor, and Ramos-Pollan, Raul, editor

Published
2019
Full Text
View/download PDF

96. Anti-HER2 Adjuvant Therapy

Author

Barrios, Carlos, Morelle, Alessandra, Novita, Guilherme, editor, Frasson, Antônio Luiz, editor, Millen, Eduardo Camargo, editor, Zerwes, Felipe, editor, and Cavalcante, Francisco Pimentel, editor

Published
2019
Full Text
View/download PDF

97. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Author

Schettini, Francesco, Chic, Nuria, Brasó-Maristany, Fara, Paré, Laia, Pascual, Tomás, Conte, Benedetta, Martínez-Sáez, Olga, Adamo, Barbara, Vidal, Maria, Barnadas, Esther, Fernández-Martinez, Aranzazu, González-Farre, Blanca, Sanfeliu, Esther, Cejalvo, Juan Miguel, Perrone, Giuseppe, Sabarese, Giovanna, Zalfa, Francesca, Peg, Vicente, Fasani, Roberta, Villagrasa, Patricia, Gavilá, Joaquín, Barrios, Carlos H., Lluch, Ana, Martín, Miguel, Locci, Mariavittoria, De Placido, Sabino, and Prat, Aleix

Published
2021
Full Text
View/download PDF

100. White pupae phenotype of tephritids is caused by parallel mutations of a MFS transporter

Author

Ward, Christopher M., Aumann, Roswitha A., Whitehead, Mark A., Nikolouli, Katerina, Leveque, Gary, Gouvi, Georgia, Fung, Elisabeth, Reiling, Sarah J., Djambazian, Haig, Hughes, Margaret A., Whiteford, Sam, Caceres-Barrios, Carlos, Nguyen, Thu N. M., Choo, Amanda, Crisp, Peter, Sim, Sheina B., Geib, Scott M., Marec, František, Häcker, Irina, Ragoussis, Jiannis, Darby, Alistair C., Bourtzis, Kostas, Baxter, Simon W., and Schetelig, Marc F.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results